366 results
Page 2 of 19
424B5
i0lio
5 May 23
Prospectus supplement for primary offering
4:49pm
424B5
68ysnd okix
3 May 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
9ri4ap3ppzskm7gsm
3 May 23
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
6:35am
8-K
EX-99.1
gj6 3wu1be
28 Apr 23
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
6:36am
8-K
EX-99.1
uocizr6
6 Apr 23
ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors
6:35am
8-K
EX-99.1
64a5aouc3x
28 Dec 22
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
4:40pm
8-K
EX-99.1
w6ucz
14 Nov 22
ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
5:23pm
8-K
EX-99.1
zd6 vpo5vbs4
4 Nov 22
ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results
6:41am
8-K
EX-99.1
uuk1w758ypqj2
1 Nov 22
ImmunoGen Announces Departure of Chief Commercial Officer
9:09am